Season 9 · Episode 18
S9 Ep18: Bhatnagar Spotlights Ongoing Uproleselan Investigations in AML
OncLive® On Air · OncLive® On Air
August 14, 202313m 41s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.